Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
AVCT

Avacta Group Plc

AVCTLSEUnited KingdomHealthcareBiotechnologyFTSE AIM 100

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe…more

P/B131.67x
£370.15M
Market Cap
EV: £360.27M
MOM9
QUAL0
VAL0
RSK9
AVCT
£370.15M
Market Cap · EV £360.27M

Avacta Group Plc

MOM9
QUAL0
VAL0
RSK9

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe…more

Latest RNS from Avacta Group Plc

Analyst consensus: Hold

As of 22 Jul 2026, 2 analysts rate Avacta Group Plc a Hold, with 50% buy ratings and a mean price target of 82p (range 60p–101p), +22% vs the current price.

Strong buy: 0Buy: 1Hold: 1Sell: 0Strong sell: 0

Full analyst history →

More Healthcare companies